UroCCR Database: French Research Network for Kidney Cancer

Recruiting

• Conditions: Kidney Cancer
• Interventions: Procedure: Radical nephrectomy versus partial nephrectomy (according surgeon judgement)

• Registration Number: NCT03293563
• Lead Sponsor: University Hospital, Bordeaux

Brief Summary

Within the framework for kidney cancer care, with the recent diversification of treatment modalities of these tumors and the deployment of the concept of multidisciplinary team, it was considered necessary to adapt the research tools to reality of health-care for patients with kidney cancer.

UroCCR is the French research network for kidney cancer, funded by the French National Cancer Institute as part of the call for projects for clinical and biological databases (BCB). Depending on the case presentation and disease evolution, more than a thousand of different variables can be recorded. At the same time, biological samples (plasma, urine, healthy and tumor tissues) are collected.

This database contains a considerable number of information and high added value since it is the result of multiple expertises that make it not only a multidisciplinary tool but also multicenter, allowing fundamental, translational and clinical research.

Detailed Description

The UroCCR database is a national medico-scientific network focused on therapeutic management and applied research in kidney cancer.

Secondary objectives:

1. - Evaluate and compare different surgical approaches in the treatment of kidney cancer,

2. - Evaluate and compare safety/efficacy of different drugs in the treatment of kidney cancer.

Study Timeline

• Study Start: 2011-12
• Study First Submitted: 2016-07-12
• Study First Submitted QC: 2017-09-20
• Study First Posted: 2017-09-26
• Status Verified: 2024-08
• Last Update Submitted: 2024-11-12
• Last Update Posted: 2024-11-14
• Primary Completion: 2040-12
• Study Completion: 2040-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 30000

Inclusion Criteria

• Adult patient with kidney cancer
• Patient with no opposition to collection of its data for the study

Exclusion Criteria

none

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients	Radical nephrectomy versus partial nephrectomy (according surgeon judgement)	Adult patients with kidney cancer

Primary Outcome Measures

Name	Time	Method
Comparison of the rates of complications between radical nephrectomy and partial nephrectomy	At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years	Clinical scores

Secondary Outcome Measures

Name	Time	Method
Dosage of creatininemia to assess the renal function after surgery	At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years	Dosage of creatininemia
Safety and efficacy of medical treatment on kidney tumor size evolution	At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years	Imaging data: tumor size evolution
Progression of the tumor	At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years	Imaging data: tumor location
Comparison of the rates of mortality between radical nephrectomy and partial nephrectomy	At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years	Medical or surgical complication rates with necessity for nephrectomy or re-exploration
Safety and efficacy of medical treatment on biological parameters	At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years	Biological parameters
Dosage of MDRD GFR to assess the renal function after surgery	At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years	Dosage of MDRD GFR

Trial Locations

Locations (50)

CHU Angers; 🇫🇷 Angers, France

CHU Bordeaux; 🇫🇷 Bordeaux, France

Clinique TIVOLI-DUCOS; 🇫🇷 Bordeaux, France

Polyclinique Médipôle Saint-Roch_Cabestany; 🇫🇷 Cabestany, France

CHU Caen; 🇫🇷 Caen, France

CHU de Clermont-Ferrand; 🇫🇷 Clermont-Ferrand, France

Ch Sud Francilien; 🇫🇷 Corbeil-Essonnes, France

CHU Henri Mondor - APHP; 🇫🇷 Créteil, France

CHU de Dijon; 🇫🇷 Dijon, France

CH du Sud Seine et Marne; 🇫🇷 Fontainebleau, France

CHU Grenoble; 🇫🇷 La Tronche, France

Pôle Santé Sud; 🇫🇷 Le Mans, France

CH Libourne; 🇫🇷 Libourne, France

CHRU Lille - Centre Oscar Lambret; 🇫🇷 Lille, France

Hôpital privé La Louvière; 🇫🇷 Lille, France

CHU Limoges; 🇫🇷 Limoges, France

HCL Lyon; 🇫🇷 Lyon, France

APH Marseille; 🇫🇷 Marseille, France

Institut Paoli-Calmette; 🇫🇷 Marseille, France

CH Mont de Marsan; 🇫🇷 Mont-de-Marsan, France

Clinique du Pont de Chaume; 🇫🇷 Montauban, France

CHRU de Nancy; 🇫🇷 Nancy, France

CHU de Nantes; 🇫🇷 Nantes, France

Clinique Saint George; 🇫🇷 Nice, France

CHU de Nice; 🇫🇷 Nice, France

CHU Kremlin Bicêtre - APHP; 🇫🇷 Paris, France

CHU de Nîmes; 🇫🇷 Nîmes, France

CH St Joseph; 🇫🇷 Paris, France

Hôpital Européen Georges Pompidou - APHP; 🇫🇷 Paris, France

CHU Tenon - APHP; 🇫🇷 Paris, France

Hôpital Bichat -APHP; 🇫🇷 Paris, France

Hôpital Cochin Port-Royal - APHP; 🇫🇷 Paris, France

Hôpital Pitié Salpétrière - APHP; 🇫🇷 Paris, France

Hôpital privé des Côtes d'Armor; 🇫🇷 Plérin, France

CHU Poitiers; 🇫🇷 Poitiers, France

Hôpital privé Claude Galien; 🇫🇷 Quincy-sous-Sénart, France

Polyclinique Francheville; 🇫🇷 Périgueux, France

CHU Reims; 🇫🇷 Reims, France

Clinique La Croix Du Sud; 🇫🇷 Quint-Fonsegrives, France

CHU Rennes - Centre Eugène Marquis; 🇫🇷 Rennes, France

CHU Rouen; 🇫🇷 Rouen, France

Clinique Santé Atlantique de Nantes; 🇫🇷 Saint-Herblain, France

Clinique Urologique Nantes Atlantis; 🇫🇷 Saint-Herblain, France

CHU St-Etienne; 🇫🇷 Saint-Étienne, France

CHU Strasbourg; 🇫🇷 Strasbourg, France

ICANS; 🇫🇷 Strasbourg, France

CHU Toulouse - Centre Claudius Régaud; 🇫🇷 Toulouse, France

Clinique Pasteur; 🇫🇷 Toulouse, France

CHRU Tours; 🇫🇷 Tours, France

Centre Hospitalier de Kourou; 🇬🇫 Kourou, French Guiana